Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$82.10
-1.8%
$93.49
$69.81
▼
$148.83
$7.32B1.36779,039 shs1.37 million shs
Alkermes plc stock logo
ALKS
Alkermes
$45.45
-2.3%
$43.68
$27.00
▼
$55.67
$7.82B0.321.64 million shs932,615 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$40.15
-0.5%
$51.49
$39.79
▼
$63.45
$3.92B1.921.68 million shs4.11 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$2.72
-6.2%
$3.75
$2.50
▼
$5.24
$1.81B1.1520.37 million shs40.84 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-4.53%-3.90%-5.13%-29.70%-24.26%
Alkermes plc stock logo
ALKS
Alkermes
-1.21%+0.63%+12.71%-6.10%+59.99%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-4.43%-19.32%-18.03%-23.79%-23.15%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-8.81%-23.88%-16.18%-6.15%-29.95%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$82.10
-1.8%
$93.49
$69.81
▼
$148.83
$7.32B1.36779,039 shs1.37 million shs
Alkermes plc stock logo
ALKS
Alkermes
$45.45
-2.3%
$43.68
$27.00
▼
$55.67
$7.82B0.321.64 million shs932,615 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$40.15
-0.5%
$51.49
$39.79
▼
$63.45
$3.92B1.921.68 million shs4.11 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$2.72
-6.2%
$3.75
$2.50
▼
$5.24
$1.81B1.1520.37 million shs40.84 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-4.53%-3.90%-5.13%-29.70%-24.26%
Alkermes plc stock logo
ALKS
Alkermes
-1.21%+0.63%+12.71%-6.10%+59.99%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-4.43%-19.32%-18.03%-23.79%-23.15%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-8.81%-23.88%-16.18%-6.15%-29.95%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.88
Moderate Buy$155.0088.79% Upside
Alkermes plc stock logo
ALKS
Alkermes
2.65
Moderate Buy$55.7322.63% Upside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.65
Moderate Buy$72.9381.64% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.20
Hold$7.58178.68% Upside

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, ABVX, and ALKS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Lower Price TargetOverweight$10.00 ➝ $7.00
11/10/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingOverweight$110.00
11/4/2026
Alkermes plc stock logo
ALKS
Alkermes
Reiterated RatingHold (C)
11/4/2026
Alkermes plc stock logo
ALKS
Alkermes
Boost Price TargetOverweight$65.00 ➝ $68.00
11/4/2026
Alkermes plc stock logo
ALKS
Alkermes
Set Price Target$61.00
11/4/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Lower Price TargetEqual Weight$75.00 ➝ $70.00
11/4/2026
Alkermes plc stock logo
ALKS
Alkermes
Boost Price TargetOutperform$56.00 ➝ $57.00
11/4/2026
Alkermes plc stock logo
ALKS
Alkermes
Boost Price TargetNeutral$43.00 ➝ $50.00
11/4/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Boost Price TargetBuy$88.00 ➝ $90.00
11/3/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingMarket Outperform
11/3/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingBuy$82.00
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$6.57 per shareN/A
Alkermes plc stock logo
ALKS
Alkermes
$1.48B5.17$1.64 per share27.79$11.10 per share4.09
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$3.51M1,109.56N/AN/A$16.99 per share2.36
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$74.68M22.68N/AN/A$1.45 per share1.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$380.27M-$6.06N/AN/AN/AN/A-91.69%-71.96%12/21/2026 (Estimated)
Alkermes plc stock logo
ALKS
Alkermes
$241.66M-$0.021,551.00126.25N/A-0.02%0.40%0.19%N/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$4.74N/AN/AN/A-1,812.07%-25.59%-17.89%N/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$644.76M-$0.90N/AN/AN/A-697.15%-47.85%-36.26%N/A

Latest RXRX, CRSP, ABVX, and ALKS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Alkermes plc stock logo
ALKS
Alkermes
-$0.0818$0.09+$0.1718$0.09$463.48 million$480.13 million
11/2/2026Q3 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.06-$1.15-$0.09-$1.15$14.75 million$12.67 million
11/2/2026Q3 2026 & Study Update
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.2190-$0.22-$0.0010-$0.22$14.81 million$18.55 million
9/21/2026Q2 2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9170-$1.71-$0.7930-$1.68$0.80 million$1.37 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
5.97
5.97
Alkermes plc stock logo
ALKS
Alkermes
0.79
2.42
2.02
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.36
16.21
16.21
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/A
5.01
5.01

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
Alkermes plc stock logo
ALKS
Alkermes
95.21%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
Alkermes plc stock logo
ALKS
Alkermes
4.59%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
5.20%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
6.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
9887.55 millionN/AOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,050168.04 million160.33 millionOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
39397.00 million91.96 millionOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
600622.76 million581.35 millionOptionable

Recent News About These Companies

Recursion Pharmaceuticals Earnings Call Signals Clinical Momentum
2 healthcare stocks to turn $10 into $100 by next year
Recursion to Participate in Upcoming Investor Conferences

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abivax stock logo

Abivax NASDAQ:ABVX

$82.10 -1.51 (-1.81%)
Closing price 04:00 PM Eastern
Extended Trading
$83.46 +1.36 (+1.66%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Alkermes stock logo

Alkermes NASDAQ:ALKS

$45.45 -1.08 (-2.32%)
Closing price 04:00 PM Eastern
Extended Trading
$45.28 -0.17 (-0.36%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$40.15 -0.22 (-0.54%)
Closing price 04:00 PM Eastern
Extended Trading
$40.65 +0.50 (+1.23%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$2.72 -0.18 (-6.21%)
Closing price 04:00 PM Eastern
Extended Trading
$2.86 +0.14 (+4.96%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.